BRPI0520530A2 - método para predizer ou monitorar a resposta de um paciente a uma droga receptora do erbb - Google Patents

método para predizer ou monitorar a resposta de um paciente a uma droga receptora do erbb

Info

Publication number
BRPI0520530A2
BRPI0520530A2 BRPI0520530-1A BRPI0520530A BRPI0520530A2 BR PI0520530 A2 BRPI0520530 A2 BR PI0520530A2 BR PI0520530 A BRPI0520530 A BR PI0520530A BR PI0520530 A2 BRPI0520530 A2 BR PI0520530A2
Authority
BR
Brazil
Prior art keywords
patient
predicting
monitoring
response
erbb receptor
Prior art date
Application number
BRPI0520530-1A
Other languages
English (en)
Inventor
Kazuto Nishio
Hideharu Kimura
Kazuo Kasahara
Original Assignee
Astrazeneca Uk Ltd
Nat Cancer Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd, Nat Cancer Ct filed Critical Astrazeneca Uk Ltd
Publication of BRPI0520530A2 publication Critical patent/BRPI0520530A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Resumo de patente de Invenção: "MéTODO PARA PREDIZER OU MONITORAR A RESPOSTA DE UM PACIENTE A UMA DROGA RECEPTORA DO ERBB". A presente invenção fornece um método para detecção de mutações do receptor do ErbE compreendendo as etapas de fornecer uma amostra de fluido biológico de um paciente; extração do DNA da dita amostra; e a avaliação do dito DNA quanto à presença de uma ou mais mutações que alteram a atividade da tirosina quinase no receptor.
BRPI0520530-1A 2005-10-05 2005-10-20 método para predizer ou monitorar a resposta de um paciente a uma droga receptora do erbb BRPI0520530A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2005003823 2005-10-05
PCT/GB2005/004036 WO2007039705A1 (en) 2005-10-05 2005-10-20 Method to predict or monitor the response of a patient to an erbb receptor drug

Publications (1)

Publication Number Publication Date
BRPI0520530A2 true BRPI0520530A2 (pt) 2009-09-29

Family

ID=36114238

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0520530-1A BRPI0520530A2 (pt) 2005-10-05 2005-10-20 método para predizer ou monitorar a resposta de um paciente a uma droga receptora do erbb

Country Status (14)

Country Link
US (1) US20080286785A1 (pt)
EP (1) EP1931798A1 (pt)
JP (1) JP2009511008A (pt)
KR (1) KR20080028857A (pt)
CN (1) CN101351563A (pt)
AU (1) AU2005337051A1 (pt)
BR (1) BRPI0520530A2 (pt)
CA (1) CA2624613A1 (pt)
IL (1) IL189705A0 (pt)
NO (1) NO20081198L (pt)
NZ (1) NZ566387A (pt)
TW (1) TW200714716A (pt)
WO (1) WO2007039705A1 (pt)
ZA (1) ZA200802854B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101313702B1 (ko) 2005-02-03 2013-10-04 와이어쓰 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
EP1942937A1 (en) 2005-11-04 2008-07-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
KR101598229B1 (ko) 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ3에 대한 항체 및 이의 용도
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
BRPI0914790A2 (pt) 2008-06-17 2015-10-20 Wyeth Llc uso de um composto de vinorelbina e um composto de hki-272, composição farmacêutica e produto e kit para o tratamento de neoplasma
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
WO2010019952A2 (en) 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
DK3000467T3 (da) 2009-04-06 2023-03-27 Wyeth Llc Behandling med neratinib mod brystkræft
TWI546537B (zh) * 2009-05-19 2016-08-21 維維亞生技公司 提供針對血液腫瘤之體外個人化藥物測試之方法
EP2896632B1 (en) * 2009-11-13 2017-10-25 Daiichi Sankyo Europe GmbH Material and methods for treating or preventing HER-3 associated diseases
CA2780875A1 (en) 2009-11-13 2011-05-19 Pangaea Biotech, S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
KR101798679B1 (ko) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
JP5859274B2 (ja) * 2010-10-29 2016-02-10 アークレイ株式会社 Ｅｇｆｒ遺伝子の多型検出用プローブ、増幅用プライマーおよびその用途
WO2012065071A2 (en) * 2010-11-12 2012-05-18 The Broad Institute Of Mit And Harvard Methods of predicting response to egfr antibody therapy
EP2468883A1 (en) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
EP2492688A1 (en) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
CN107419018B (zh) * 2012-02-16 2020-09-04 江苏宏微特斯医药科技有限公司 一种基于Blocker引物和ARMS引物检测基因突变的方法和试剂盒
WO2013190089A1 (en) 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Molecular biomarkers for predicting outcome in lung cancer
ES2662598T3 (es) * 2013-03-08 2018-04-09 F. Hoffmann-La Roche Ag Análisis de sangre para la detección de mutaciones de EGFR
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
EP3204510B1 (en) * 2014-10-09 2018-07-25 Roche Diagnostics GmbH Mutations in the epidermal growth factor receptor kinase domain
GB201507202D0 (en) 2015-04-28 2015-06-10 Stfc Science & Technology Receptor tyosine kinase biomarkers
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
CN115737637A (zh) * 2017-01-10 2023-03-07 王巍 拉索昔芬调节膜结合雌激素信号的应用及治疗癌症的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9403953D0 (sv) * 1994-07-15 1994-11-16 Pharmacia Biotech Ab Sequence-based diagnosis
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
GB9812768D0 (en) * 1998-06-13 1998-08-12 Zeneca Ltd Methods
WO2005085473A2 (en) * 2004-03-01 2005-09-15 University Of Chicago Polymorphisms in the epidermal growth factor receptor gene promoter
ES2425749T3 (es) * 2004-03-31 2013-10-17 The General Hospital Corporation Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico
EP3042964A1 (en) * 2004-06-04 2016-07-13 Genentech, Inc. Egfr mutations
GB2424886A (en) * 2005-04-04 2006-10-11 Dxs Ltd Polynucleotide primers against epidermal growth factor receptor and method of detecting gene mutations
US20060223178A1 (en) * 2005-04-05 2006-10-05 Tom Barber Devices and methods for magnetic enrichment of cells and other particles

Also Published As

Publication number Publication date
KR20080028857A (ko) 2008-04-01
AU2005337051A1 (en) 2007-04-12
IL189705A0 (en) 2008-06-05
NZ566387A (en) 2010-05-28
CN101351563A (zh) 2009-01-21
ZA200802854B (en) 2009-06-24
JP2009511008A (ja) 2009-03-19
CA2624613A1 (en) 2007-04-12
WO2007039705A1 (en) 2007-04-12
US20080286785A1 (en) 2008-11-20
EP1931798A1 (en) 2008-06-18
NO20081198L (no) 2008-06-30
TW200714716A (en) 2007-04-16

Similar Documents

Publication Publication Date Title
BRPI0520530A2 (pt) método para predizer ou monitorar a resposta de um paciente a uma droga receptora do erbb
WO2007089731A3 (en) Ocular fluid markers
Carlberg et al. Brain-derived neurotrophic factor (BDNF)—Epigenetic regulation in unipolar and bipolar affective disorder
WO2009117122A3 (en) Genetic analysis
BRPI0914020A2 (pt) método para detecção e/ou o diagnóstico de uma ou mais causas de distúrbio do ritmo do coração, sistema para a detecção e/ou o tratamento de uma ou mais causas de um distúrbio do ritmo do coração, método para o tratamento de distúrbio do ritmo do coração, dispositivo sensor ajustável para detectar distúrbios do ritmo do coração, método para a detecção e/ou o diagnóstico de uma ou mais causas de um distúrbio do ritmo biológico, sistema para a detecção e/ou o tratamento de uma ou mais causas de um distúrbio do ritmo biológico e método para o tratamento de um distúrbio do ritmo biológico
BRPI0508286A (pt) métodos para determinar a possibilidade de efetividade de um tratamento seletivo de receptor de fator de crescimento epidérmico em um paciente, para tratar um paciente e para selecionar um composto que inibe a atividade catalìtica de cinase de um receptor de fator de crescimento epidérmico variante, sonda, kit, composto que inibe a atividade catalìtica de cinase de um receptor de fator de crescimento epidérmico variante, composição farmacêutica, ácido nucléico e proteìna isolada
EP2506914A4 (en) ANALYTICAL MONITORING AND LIQUID DISPENSING SYSTEM
DK2114990T5 (da) Fremgangsmåde til forudsigelse af NSCLC-patienters respons på behandling med en EGFR-TK-inhibitor
WO2007070376A3 (en) Diagnosis, prognosis and monitoring of disease progression of systemic lupus erythematosus through blood leukocyte microarray analysis
WO2007123976A3 (en) Antibody profiling for determination of patient responsiveness
EP2029009A4 (en) EEG ANALYSIS SYSTEM
EP3330703A3 (en) Lipoprotein analysis by differential charged-particle mobility
EP2503338A3 (en) CD73 as a biomarker for monitoring development of diseases and assessing the efficacy of therapies
WO2009041501A1 (ja) ヘルペスウイルスの潜伏感染に関与する因子及びその利用
BR112022008391A2 (pt) Sistemas de ensaio de fluxo lateral e métodos para quantificação de amostra biológica
Egashira et al. Disruption of the prepulse inhibition of the startle reflex in vasopressin V1b receptor knockout mice: reversal by antipsychotic drugs
BR112012007812A2 (pt) métodos de quantificação de organismos-alvo e criação de plantas de algodão resistentes reniforme.
EA200701602A1 (ru) Способ прогнозирования психических заболеваний, например аутизма и церебрального паралича
WO2010121834A3 (en) Irak kinase family as novel target and biomarker for alzheimer
EP2151496A4 (en) METHOD FOR EVALUATING ACTIVE SENSITIVITY BY ANALYSIS OF THE POMC GENE
EP1670497A4 (en) METHOD FOR IDENTIFYING MODULATORS OF PROTEIN KINASE C EPSILON (PKC Ε) AND METHOD FOR TREATING THEREOF CONVERTING DERIVED GLUCOSE METABOLISM
BRPI0415941A (pt) recipiente de filtro de espécime dotado de armazenamento de dados
WO2007127002A3 (en) Protein markers of responsiveness to type iii receptor tyrosine kinase inhibitors
Maddrey et al. Evaluation of Hepatobiliary Parameters During Eltrombopag Treatment in Patients with Chronic Immune Thrombocytopenic Purpura.
WO2008047129A3 (en) Latent fluorescent probes

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO EM SUA FORMA AUTENTICADA, EM NOME DE TODOS OS DEPOSITANTES; OU SEGUNDO O PARECER DA PROCURADORIA NO 074/93, DEVE CONSTAR UMA DECLARACAO DE VERACIDADE, A QUAL DEVE SER ASSINADA POR UMA PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O (OS) INTERESSADO (S), DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO, OU NO SEU SUBSTABELECIMENTO.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.